Subtherapeutic oral anticoagulant therapy: Frequency and risk factors

Summary Subtherapeutic anticoagulation levels increase both the risk and severity of thromboembolism. The aim of this study was to determine the cumulative incidence of subtherapeutic international normalised ratios (INRs) and to identify risk factors associated with a low INR. We performed a cohort...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Thrombosis and haemostasis 2009-03, Vol.101 (3), p.552-556
Hauptverfasser: Rombouts, Eva K., Rosendaal, Frits R., van der Meer, Felix J. M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 556
container_issue 3
container_start_page 552
container_title Thrombosis and haemostasis
container_volume 101
creator Rombouts, Eva K.
Rosendaal, Frits R.
van der Meer, Felix J. M.
description Summary Subtherapeutic anticoagulation levels increase both the risk and severity of thromboembolism. The aim of this study was to determine the cumulative incidence of subtherapeutic international normalised ratios (INRs) and to identify risk factors associated with a low INR. We performed a cohort study in 7,419 patients from a Dutch anticoagulation clinic. Patients who started a first treatment with oral anticoagulants between January 2000 and December 2005 and who were stably anticoagulated (4 consecutive INRs in the therapeutic range) were included. Within the cohort a nested case control study was performed to identify risk factors of subtherapeutic INRs and to determine how often a subtherapeutic INR is the result of medical interference in case of invasive procedures, hospital admissions, haemorrhage or overanticoagulation. In patients with a stable anticoagulation, the median time to a first low INR was 40 weeks. A subtherapeutic INR occurred twice as often in patients using acenocoumarol as in those using phenprocoumon (hazard ratio [HR] 2.1, 95% confidence interval [95%CI]:2.0 – 2.3) and was more common in patients with a high therapeutic range compared to a low therapeutic range (HR 1.8, 95%CI:1.5 – 2.2). Occurrence of a low INR also depended on indication for anticoagulant therapy, with the highest risk in patients who used anticoagulants as prophylaxis and the lowest risk in patients with mechanical heart valves. In 30% of cases the subtherapeutic INR was preceded by an event necessitating vitamin K or discontinuation of the anticoagulant drug.
doi_str_mv 10.1160/TH08-09-0626
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1160_TH08_09_0626</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19277419</sourcerecordid><originalsourceid>FETCH-LOGICAL-c650t-fb8c725e74bb558e604fd3e57e72fd40494b1bd6363e5fdbe4587c6aab414e6e3</originalsourceid><addsrcrecordid>eNq9kE2L1TAUhoMoznV051q6caXVpDcfjTsZZhxhwIUjuAtJempzbZuaD-X-e1N6GQVxJ65ycs7DeTgvQk8JfkUIx69vr3FbY1lj3vB7aNcwLmreys_30Q7vKa55Q9kZehTjAWPCqWQP0RmRjRCUyB26_JhNGiDoBXJytvJBj5WeS-n1lzyWqtrGxzfVVYBvGWZ7LEBXBRe_Vr22yYf4GD3o9Rjhyek9R5-uLm8vruubD-_eX7y9qS1nONW9aa1oGAhqDGMtcEz7bg9MgGj6jmIqqSGm43temn1ngLJWWK61oYQCh_05ernttcHHGKBXS3CTDkdFsFrTUGsaCku1plHwZxu-ZDNB9ws-nV-A5ydAR6vHPujZunjHNYS0kjFWuBcblwYHE6iDz2Euh_5N2210tINOSWcIdyvTEPxkfCyWEqIaNEw-Jr3-rZ8TzKkMgh3cd1AuxgwqLmCdHtWk5xxtcEsqVilXzeEfagQRfyhUHPwPNaRpLLL5P9z0m_AncFXz2Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Subtherapeutic oral anticoagulant therapy: Frequency and risk factors</title><source>MEDLINE</source><source>Thieme Connect Journals</source><creator>Rombouts, Eva K. ; Rosendaal, Frits R. ; van der Meer, Felix J. M.</creator><creatorcontrib>Rombouts, Eva K. ; Rosendaal, Frits R. ; van der Meer, Felix J. M.</creatorcontrib><description>Summary Subtherapeutic anticoagulation levels increase both the risk and severity of thromboembolism. The aim of this study was to determine the cumulative incidence of subtherapeutic international normalised ratios (INRs) and to identify risk factors associated with a low INR. We performed a cohort study in 7,419 patients from a Dutch anticoagulation clinic. Patients who started a first treatment with oral anticoagulants between January 2000 and December 2005 and who were stably anticoagulated (4 consecutive INRs in the therapeutic range) were included. Within the cohort a nested case control study was performed to identify risk factors of subtherapeutic INRs and to determine how often a subtherapeutic INR is the result of medical interference in case of invasive procedures, hospital admissions, haemorrhage or overanticoagulation. In patients with a stable anticoagulation, the median time to a first low INR was 40 weeks. A subtherapeutic INR occurred twice as often in patients using acenocoumarol as in those using phenprocoumon (hazard ratio [HR] 2.1, 95% confidence interval [95%CI]:2.0 – 2.3) and was more common in patients with a high therapeutic range compared to a low therapeutic range (HR 1.8, 95%CI:1.5 – 2.2). Occurrence of a low INR also depended on indication for anticoagulant therapy, with the highest risk in patients who used anticoagulants as prophylaxis and the lowest risk in patients with mechanical heart valves. In 30% of cases the subtherapeutic INR was preceded by an event necessitating vitamin K or discontinuation of the anticoagulant drug.</description><identifier>ISSN: 0340-6245</identifier><identifier>EISSN: 2567-689X</identifier><identifier>DOI: 10.1160/TH08-09-0626</identifier><identifier>PMID: 19277419</identifier><identifier>CODEN: THHADQ</identifier><language>eng</language><publisher>Stuttgart: Schattauer Verlag für Medizin und Naturwissenschaften</publisher><subject>Acenocoumarol - administration &amp; dosage ; Acenocoumarol - adverse effects ; Acenocoumarol - therapeutic use ; Adult ; Aged ; Aged, 80 and over ; anticoagulant stability ; Anticoagulants - administration &amp; dosage ; Anticoagulants - adverse effects ; Anticoagulants - therapeutic use ; Biological and medical sciences ; Blood coagulation. Blood cells ; Cohort Studies ; Female ; Fundamental and applied biological sciences. Psychology ; Hematologic and hematopoietic diseases ; Hemorrhage - etiology ; Humans ; INR ; International Normalized Ratio ; Male ; Medical sciences ; Middle Aged ; Molecular and cellular biology ; New Technologies, Diagnostic Tools and Drugs ; oral anticoagulants ; Phenprocoumon - administration &amp; dosage ; Phenprocoumon - adverse effects ; Phenprocoumon - therapeutic use ; Platelet diseases and coagulopathies ; Risk Factors ; Thromboembolism - etiology ; Thromboembolism - prevention &amp; control ; Time Factors</subject><ispartof>Thrombosis and haemostasis, 2009-03, Vol.101 (3), p.552-556</ispartof><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c650t-fb8c725e74bb558e604fd3e57e72fd40494b1bd6363e5fdbe4587c6aab414e6e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.thieme-connect.de/products/ejournals/pdf/10.1160/TH08-09-0626.pdf$$EPDF$$P50$$Gthieme$$H</linktopdf><linktohtml>$$Uhttps://www.thieme-connect.de/products/ejournals/html/10.1160/TH08-09-0626$$EHTML$$P50$$Gthieme$$H</linktohtml><link.rule.ids>314,776,780,3005,27901,27902,54534,54535</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=21189555$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19277419$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rombouts, Eva K.</creatorcontrib><creatorcontrib>Rosendaal, Frits R.</creatorcontrib><creatorcontrib>van der Meer, Felix J. M.</creatorcontrib><title>Subtherapeutic oral anticoagulant therapy: Frequency and risk factors</title><title>Thrombosis and haemostasis</title><addtitle>Thromb Haemost</addtitle><description>Summary Subtherapeutic anticoagulation levels increase both the risk and severity of thromboembolism. The aim of this study was to determine the cumulative incidence of subtherapeutic international normalised ratios (INRs) and to identify risk factors associated with a low INR. We performed a cohort study in 7,419 patients from a Dutch anticoagulation clinic. Patients who started a first treatment with oral anticoagulants between January 2000 and December 2005 and who were stably anticoagulated (4 consecutive INRs in the therapeutic range) were included. Within the cohort a nested case control study was performed to identify risk factors of subtherapeutic INRs and to determine how often a subtherapeutic INR is the result of medical interference in case of invasive procedures, hospital admissions, haemorrhage or overanticoagulation. In patients with a stable anticoagulation, the median time to a first low INR was 40 weeks. A subtherapeutic INR occurred twice as often in patients using acenocoumarol as in those using phenprocoumon (hazard ratio [HR] 2.1, 95% confidence interval [95%CI]:2.0 – 2.3) and was more common in patients with a high therapeutic range compared to a low therapeutic range (HR 1.8, 95%CI:1.5 – 2.2). Occurrence of a low INR also depended on indication for anticoagulant therapy, with the highest risk in patients who used anticoagulants as prophylaxis and the lowest risk in patients with mechanical heart valves. In 30% of cases the subtherapeutic INR was preceded by an event necessitating vitamin K or discontinuation of the anticoagulant drug.</description><subject>Acenocoumarol - administration &amp; dosage</subject><subject>Acenocoumarol - adverse effects</subject><subject>Acenocoumarol - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>anticoagulant stability</subject><subject>Anticoagulants - administration &amp; dosage</subject><subject>Anticoagulants - adverse effects</subject><subject>Anticoagulants - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood coagulation. Blood cells</subject><subject>Cohort Studies</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hemorrhage - etiology</subject><subject>Humans</subject><subject>INR</subject><subject>International Normalized Ratio</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular and cellular biology</subject><subject>New Technologies, Diagnostic Tools and Drugs</subject><subject>oral anticoagulants</subject><subject>Phenprocoumon - administration &amp; dosage</subject><subject>Phenprocoumon - adverse effects</subject><subject>Phenprocoumon - therapeutic use</subject><subject>Platelet diseases and coagulopathies</subject><subject>Risk Factors</subject><subject>Thromboembolism - etiology</subject><subject>Thromboembolism - prevention &amp; control</subject><subject>Time Factors</subject><issn>0340-6245</issn><issn>2567-689X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNq9kE2L1TAUhoMoznV051q6caXVpDcfjTsZZhxhwIUjuAtJempzbZuaD-X-e1N6GQVxJ65ycs7DeTgvQk8JfkUIx69vr3FbY1lj3vB7aNcwLmreys_30Q7vKa55Q9kZehTjAWPCqWQP0RmRjRCUyB26_JhNGiDoBXJytvJBj5WeS-n1lzyWqtrGxzfVVYBvGWZ7LEBXBRe_Vr22yYf4GD3o9Rjhyek9R5-uLm8vruubD-_eX7y9qS1nONW9aa1oGAhqDGMtcEz7bg9MgGj6jmIqqSGm43temn1ngLJWWK61oYQCh_05ernttcHHGKBXS3CTDkdFsFrTUGsaCku1plHwZxu-ZDNB9ws-nV-A5ydAR6vHPujZunjHNYS0kjFWuBcblwYHE6iDz2Euh_5N2210tINOSWcIdyvTEPxkfCyWEqIaNEw-Jr3-rZ8TzKkMgh3cd1AuxgwqLmCdHtWk5xxtcEsqVilXzeEfagQRfyhUHPwPNaRpLLL5P9z0m_AncFXz2Q</recordid><startdate>20090301</startdate><enddate>20090301</enddate><creator>Rombouts, Eva K.</creator><creator>Rosendaal, Frits R.</creator><creator>van der Meer, Felix J. M.</creator><general>Schattauer Verlag für Medizin und Naturwissenschaften</general><general>Schattauer GmbH</general><general>Schattauer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20090301</creationdate><title>Subtherapeutic oral anticoagulant therapy: Frequency and risk factors</title><author>Rombouts, Eva K. ; Rosendaal, Frits R. ; van der Meer, Felix J. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c650t-fb8c725e74bb558e604fd3e57e72fd40494b1bd6363e5fdbe4587c6aab414e6e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Acenocoumarol - administration &amp; dosage</topic><topic>Acenocoumarol - adverse effects</topic><topic>Acenocoumarol - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>anticoagulant stability</topic><topic>Anticoagulants - administration &amp; dosage</topic><topic>Anticoagulants - adverse effects</topic><topic>Anticoagulants - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood coagulation. Blood cells</topic><topic>Cohort Studies</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hemorrhage - etiology</topic><topic>Humans</topic><topic>INR</topic><topic>International Normalized Ratio</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular and cellular biology</topic><topic>New Technologies, Diagnostic Tools and Drugs</topic><topic>oral anticoagulants</topic><topic>Phenprocoumon - administration &amp; dosage</topic><topic>Phenprocoumon - adverse effects</topic><topic>Phenprocoumon - therapeutic use</topic><topic>Platelet diseases and coagulopathies</topic><topic>Risk Factors</topic><topic>Thromboembolism - etiology</topic><topic>Thromboembolism - prevention &amp; control</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rombouts, Eva K.</creatorcontrib><creatorcontrib>Rosendaal, Frits R.</creatorcontrib><creatorcontrib>van der Meer, Felix J. M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rombouts, Eva K.</au><au>Rosendaal, Frits R.</au><au>van der Meer, Felix J. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Subtherapeutic oral anticoagulant therapy: Frequency and risk factors</atitle><jtitle>Thrombosis and haemostasis</jtitle><addtitle>Thromb Haemost</addtitle><date>2009-03-01</date><risdate>2009</risdate><volume>101</volume><issue>3</issue><spage>552</spage><epage>556</epage><pages>552-556</pages><issn>0340-6245</issn><eissn>2567-689X</eissn><coden>THHADQ</coden><abstract>Summary Subtherapeutic anticoagulation levels increase both the risk and severity of thromboembolism. The aim of this study was to determine the cumulative incidence of subtherapeutic international normalised ratios (INRs) and to identify risk factors associated with a low INR. We performed a cohort study in 7,419 patients from a Dutch anticoagulation clinic. Patients who started a first treatment with oral anticoagulants between January 2000 and December 2005 and who were stably anticoagulated (4 consecutive INRs in the therapeutic range) were included. Within the cohort a nested case control study was performed to identify risk factors of subtherapeutic INRs and to determine how often a subtherapeutic INR is the result of medical interference in case of invasive procedures, hospital admissions, haemorrhage or overanticoagulation. In patients with a stable anticoagulation, the median time to a first low INR was 40 weeks. A subtherapeutic INR occurred twice as often in patients using acenocoumarol as in those using phenprocoumon (hazard ratio [HR] 2.1, 95% confidence interval [95%CI]:2.0 – 2.3) and was more common in patients with a high therapeutic range compared to a low therapeutic range (HR 1.8, 95%CI:1.5 – 2.2). Occurrence of a low INR also depended on indication for anticoagulant therapy, with the highest risk in patients who used anticoagulants as prophylaxis and the lowest risk in patients with mechanical heart valves. In 30% of cases the subtherapeutic INR was preceded by an event necessitating vitamin K or discontinuation of the anticoagulant drug.</abstract><cop>Stuttgart</cop><pub>Schattauer Verlag für Medizin und Naturwissenschaften</pub><pmid>19277419</pmid><doi>10.1160/TH08-09-0626</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0340-6245
ispartof Thrombosis and haemostasis, 2009-03, Vol.101 (3), p.552-556
issn 0340-6245
2567-689X
language eng
recordid cdi_crossref_primary_10_1160_TH08_09_0626
source MEDLINE; Thieme Connect Journals
subjects Acenocoumarol - administration & dosage
Acenocoumarol - adverse effects
Acenocoumarol - therapeutic use
Adult
Aged
Aged, 80 and over
anticoagulant stability
Anticoagulants - administration & dosage
Anticoagulants - adverse effects
Anticoagulants - therapeutic use
Biological and medical sciences
Blood coagulation. Blood cells
Cohort Studies
Female
Fundamental and applied biological sciences. Psychology
Hematologic and hematopoietic diseases
Hemorrhage - etiology
Humans
INR
International Normalized Ratio
Male
Medical sciences
Middle Aged
Molecular and cellular biology
New Technologies, Diagnostic Tools and Drugs
oral anticoagulants
Phenprocoumon - administration & dosage
Phenprocoumon - adverse effects
Phenprocoumon - therapeutic use
Platelet diseases and coagulopathies
Risk Factors
Thromboembolism - etiology
Thromboembolism - prevention & control
Time Factors
title Subtherapeutic oral anticoagulant therapy: Frequency and risk factors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T13%3A45%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Subtherapeutic%20oral%20anticoagulant%20therapy:%20Frequency%20and%20risk%20factors&rft.jtitle=Thrombosis%20and%20haemostasis&rft.au=Rombouts,%20Eva%20K.&rft.date=2009-03-01&rft.volume=101&rft.issue=3&rft.spage=552&rft.epage=556&rft.pages=552-556&rft.issn=0340-6245&rft.eissn=2567-689X&rft.coden=THHADQ&rft_id=info:doi/10.1160/TH08-09-0626&rft_dat=%3Cpubmed_cross%3E19277419%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/19277419&rfr_iscdi=true